PE20020382A1 - Derivados de acido heteroarilalcanoico como antagonistas de la integrina - Google Patents

Derivados de acido heteroarilalcanoico como antagonistas de la integrina

Info

Publication number
PE20020382A1
PE20020382A1 PE2001000576A PE2001000576A PE20020382A1 PE 20020382 A1 PE20020382 A1 PE 20020382A1 PE 2001000576 A PE2001000576 A PE 2001000576A PE 2001000576 A PE2001000576 A PE 2001000576A PE 20020382 A1 PE20020382 A1 PE 20020382A1
Authority
PE
Peru
Prior art keywords
methyl
alkyl
derivatives
ilamine
oxadiazol
Prior art date
Application number
PE2001000576A
Other languages
English (en)
Inventor
Nizal Samuel Chandrakumar
Barbara B Chen
Michael Clare
Balekudru Devadas
Alan F Gasiecki
Mark Russell
Hwang-Fun Lu
Thomas D Penning
Nagarajan Srinivasan Raj Raj
Thomas Rogers
Ish Kumar Khanna
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of PE20020382A1 publication Critical patent/PE20020382A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)

Abstract

SE REFIERE A DERIVADOS DE ACIDO HETEROARILALCANOICO DE FORMULA I DONDE A ES UN ANILLO MONOCICLICO DE 4-8 MIEMBROS O UN ANILLO BICICLICO DE 7-12 MIEMBROS QUE CONTIENE 1 A 4 HETEROATOMOS SELECCIONADOS DE O, N, S OPCIONALMENTE SATURADO O INSATURADO CON ALQUILO, HALOALQUILO, ARILO HETEROARILO, CON LA CONDICION DE QUE CUANDO Y4 EN LA FORMULA I ES H, EL ANILLO A PUEDE NO SER UN OXAZOL CON UNA CADENA LATERAL QUE CONTIENEN X-Y CONECTADA EL CARBONO 2; A1 ES UN HETEROCICLO MONOCICLICO DE 5-9 MIEMBROS, POLICICLICO DE 7-14 MIEMBROS DE FORMULA a QUE CONTIENE POR LO MENOS UN ATOMO DE N DONDE RK ES OH, ALQUILO, ALCOXI, ENTRE OTROS; R2 ES H, ALQUILO, ARILO, OH, ALCOXI, ENTRE OTROS; R2 JUNTO A R7 FORMA UN HETEROCICLO QUE CONTIENE DINITROGENO DE 4-12 MIEMBROS CON ALQUILO, TIOALQUILO, ALQUILAMINO, OH, CETO, ENTRE OTROS; Y2 ES ALQUILO, CICLOALQUILO, BICICLOALQUILO, ENTRE OTROS; Z1 ES CH2, O, NH, CO, ENTRE OTROS; Z2 ES UN ENLAZANTE DE 2-5 CARBONOS; X ES S, SO2, CO, ENTRE OTROS; Y ES CO, SO2, ENTRE OTROS; Y3 E Y4 SON H, ALQUILO, HALOALQUILO, ENTRE OTROS; Y5 ES C; Rb ES OH. SON COMPUESTOS PREFERIDOS ACIDO 3-METIL-4-(3-{3-[(PIRIDIN-2-ILAMINO)METIL]FENIL-1,2,4-OXADIAZOL-5-IL-BUTANOICO, ACIDO 3-METIL-4-(3-{4-[(PIRIDIN-2-ILAMINO)METIL]FENIL-1,2,4-OXADIAZOL-5-IL-BUTANOICO, ACIDO [1-({3-[4-(PIRIDIN-2-ILAMINO)BUTIL]-1,2,4-OXADIAZOL-5-IL}METIL)CICLOPENTIL]-ACETICO, ENTRE OTROS. LOS DERIVADOS DE ACIDO HETEROARILALCANOICO SON ANTAGONISTAS DE LA INTEGRINA E INHIBEN LA ANGIOGENES, METASTASIS TUMORAL
PE2001000576A 2000-06-15 2001-06-15 Derivados de acido heteroarilalcanoico como antagonistas de la integrina PE20020382A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21178200P 2000-06-15 2000-06-15
US21178100P 2000-06-15 2000-06-15

Publications (1)

Publication Number Publication Date
PE20020382A1 true PE20020382A1 (es) 2002-05-10

Family

ID=26906455

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000576A PE20020382A1 (es) 2000-06-15 2001-06-15 Derivados de acido heteroarilalcanoico como antagonistas de la integrina

Country Status (7)

Country Link
US (2) US6933304B2 (es)
EP (1) EP1289983A2 (es)
JP (1) JP2004511434A (es)
AR (1) AR031109A1 (es)
AU (1) AU2001269876A1 (es)
PE (1) PE20020382A1 (es)
WO (1) WO2001096334A2 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6933304B2 (en) * 2000-06-15 2005-08-23 Pharmacia Corporation Heteroarylalkanoic acids as integrin receptor antagonists
ATE468325T1 (de) 2001-03-19 2010-06-15 Dainippon Sumitomo Pharma Co Arylsubstituierte alicyclische verbindung und diese enthaltende medizinische zusammensetzung
US20040224986A1 (en) 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins
CA2507958A1 (en) * 2002-12-20 2004-07-15 Pharmacia Corporation Pyrazole compounds as integrin receptor antagonists derivatives
JP2006518333A (ja) * 2002-12-20 2006-08-10 ファルマシア・コーポレーション インテグリン受容体アンタゴニストとしてのヘテロアリールアルカン酸
US7115596B2 (en) 2002-12-20 2006-10-03 Pharmacia Corporation Thiazole compounds as integrin receptor antagonists derivatives
US7351711B2 (en) 2003-07-31 2008-04-01 Janssen Pharmaceutical, N.V. Tricyclic indanyls as integrin inhibitors
US20080306116A1 (en) * 2007-06-08 2008-12-11 Christ Andreas D Aryloxazole, aryloxadiazole and benzimidazole derivatives
TW201010700A (en) * 2008-08-25 2010-03-16 Piramal Lifesciences Ltd Diacylglycerol acyltransferase inhibitors
DE112010001898T5 (de) 2009-04-27 2012-08-02 Dow Agrosciences Llc Insektizide Pyridinverbindungen
CA2784710A1 (en) * 2009-12-15 2011-06-23 Shionogi & Co., Ltd. Oxadiazole derivative having endothelial lipase inhibitory activity
AU2011224287B2 (en) 2010-03-12 2015-03-26 Omeros Corporation PDE10 inhibitors and related compositions and methods
US8716226B2 (en) 2012-07-18 2014-05-06 Saint Louis University 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists
AU2013292580B2 (en) 2012-07-18 2017-07-20 Saint Louis University Beta amino acid derivatives as integrin antagonists
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
NZ716462A (en) 2014-04-28 2017-11-24 Omeros Corp Optically active pde10 inhibitor
NZ716494A (en) 2014-04-28 2017-07-28 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417018D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417002D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
CN107530313A (zh) 2015-04-24 2018-01-02 奥默罗斯公司 Pde10抑制剂以及相关组合物和方法
US9920045B2 (en) 2015-11-04 2018-03-20 Omeros Corporation Solid state forms of a PDE10 inhibitor
CA3008023A1 (en) 2015-12-30 2017-07-06 Saint Louis University Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists
GB201604680D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
CN110167933B (zh) * 2016-11-08 2022-06-21 百时美施贵宝公司 作为αV整联蛋白抑制剂的唑酰胺和胺
AU2017393297A1 (en) * 2016-12-29 2019-06-13 Indalo Therapeutics, Inc. Integrin antagonists
CN116283977A (zh) 2017-02-28 2023-06-23 莫菲克医疗股份有限公司 αvβ6整合蛋白的抑制剂
MA47692A (fr) 2017-02-28 2020-01-08 Morphic Therapeutic Inc Inhibiteurs de l'intégrine (alpha-v) (bêta-6)
JP7182568B2 (ja) 2017-05-22 2022-12-02 トパドゥール ファーマ アーゲー 新規二重作用モード可溶性グアニル酸シクラーゼ活性化因子およびホスホジエステラーゼ阻害剤ならびにその使用
JOP20200212A1 (ar) * 2018-03-07 2020-09-01 Pliant Therapeutics Inc مركبات حمض أميني وطرق استخدامها
US20200071322A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. Inhibiting (alpha-v)(beta-6) integrin
CN109369530B (zh) * 2018-11-15 2022-03-04 河北三川化工有限公司 一种2,4-二氧-3-氮杂-螺[5,5]十一烷-1,5-二腈的制备方法
WO2021091823A1 (en) * 2019-11-06 2021-05-14 Albert Einstein College Of Medicine Small molecule prostagladin transport inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9023289D0 (en) 1990-10-25 1990-12-05 Ici Plc Herbicides
CA2144762A1 (en) * 1992-10-14 1994-04-28 George D. Hartman Fibrinogen receptor antagonists
US5849736A (en) 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
JP2000510098A (ja) 1996-03-29 2000-08-08 ジー．ディー．サール アンド カンパニー 桂皮酸誘導体
EP0889877B1 (en) * 1996-03-29 2001-08-29 G.D. Searle & Co. META-SUBSTITUTED PHENYLENE DERIVATIVES AND THEIR USE AS ALPHAvBETA3 INTEGRIN ANTAGONISTS OR INHIBITORS
DE19620041A1 (de) * 1996-05-17 1998-01-29 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
CA2309204A1 (en) 1997-11-26 1999-06-03 Dupont Pharmaceuticals Company 1,3,4-thiadiazoles and 1,3,4-oxadiazoles as .alpha.v.beta.3 antagonists
CA2315370A1 (en) * 1997-12-17 1999-06-24 Merck & Co., Inc. Integrin receptor antagonists
EP1044001B1 (en) 1997-12-17 2005-07-06 Merck & Co., Inc. Integrin receptor antagonists
CA2339666A1 (en) 1998-08-07 2000-02-17 Smithkline Beecham Corporation Vitronectin receptor antagonists
DE60035779T2 (de) 1999-06-02 2008-04-30 Merck & Co., Inc. Alpha v integrin-rezeptor antagonisten
CA2386030A1 (en) 1999-10-04 2001-04-12 Merck & Co., Inc. Integrin receptor antagonists
US6933304B2 (en) * 2000-06-15 2005-08-23 Pharmacia Corporation Heteroarylalkanoic acids as integrin receptor antagonists

Also Published As

Publication number Publication date
US20020133023A1 (en) 2002-09-19
AR031109A1 (es) 2003-09-10
AU2001269876A1 (en) 2001-12-24
US7119098B2 (en) 2006-10-10
JP2004511434A (ja) 2004-04-15
US20040092497A1 (en) 2004-05-13
EP1289983A2 (en) 2003-03-12
US6933304B2 (en) 2005-08-23
WO2001096334A2 (en) 2001-12-20
WO2001096334A3 (en) 2002-09-12

Similar Documents

Publication Publication Date Title
PE20020382A1 (es) Derivados de acido heteroarilalcanoico como antagonistas de la integrina
ATE432007T1 (de) Fungizide ternäre wirkstoffkombinationen
PE20051141A1 (es) Inhibidores de la polimerasa viral
CO5200785A1 (es) Uso terapeutico de quinazolina
EA200600315A1 (ru) Пиримидиновые соединения, их применение в качестве a-селективных антагонистов и способ их получения
PE20011313A1 (es) Activadores de glucoquinasa que contienen hidantoina
SV2007002160A (es) Inhibidores de cetp ref. b.16744/shh
NO20061107L (no) CRF-antagonister og heterobrcykliske forbindelser
PE20050147A1 (es) Derivados de pirimidina, piridina y tiazol como inhibidores de fosfatidilinositol 3-quinasa
PE20090610A1 (es) Derivados de pirazol sustituidos
CO5251452A1 (es) Oxazoles sustituidos y derivados de tiazoles como activadores de alfa hppar
PE20090770A1 (es) Derivados de benzoxazolona
RU2006147267A (ru) Конденсированное гетероциклическое соединение
TR199701218T2 (xx) Benzimidazol bile�ikleri ve bunlar� i�eren farmakolojik bile�imler.
PE20110672A1 (es) 4-fenil-1-h-pirazoles insecticidas
NZ602099A (en) Stat3 inhibitor containing quinolinecarboxamide derivative as active ingredient
CO5700817A2 (es) Compuesto pentaciclico heteroaromatico y uso medicinal del mismo
PE20001483A1 (es) Acidos oxamicos y derivados como ligandos de receptores tiroideos
ES2571327T3 (es) Composiciones plaguicidas
NZ594597A (en) Substituted piperidines as ccr3 antagonists
PE20060770A1 (es) Derivados de n-[(4,5-difenil-3-alquil-2-tienil)metil]amina como antagonistas de los receptores cannabinoides cb1
MY137761A (en) The use of n-arylhdrazine derivatives for combating non-crop pests
ES2178451T3 (es) Derivados de benzoxadiazoles, benzotiadiazoles, benzotriazoles y quinoxalinas.
PE20080143A1 (es) Compuestos 2-oxo-3-fenil-(1,4-diazaespiro[4.5]dec-3-en-1-il)acetamida sustituidos como inhibidores del transportador de glicina
PE20020269A1 (es) Derivados de pirrol como inhibidores de transcriptasa inversa del vih

Legal Events

Date Code Title Description
FD Application declared void or lapsed